New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas MD Anderson Cancer Center have developed a new computational technique to accurately differentiate between data from cancer cells and the variety of normal cells found within tumor samples. The work was published today in Nature Biotechnology.
The new tool, dubbed CopyKAT (copy number karyotyping...
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal carcinomatosis (PC), a specific form of metastatic gastric cancer, defined the extensive cellular heterogeneity and identified two distinct subtypes correlated with patient survival.
Based on their findings, published today in Nature Medicine, the researchers developed and validated a gene...
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...